Prognostic Factors In Stage Ii Colon Cancer After Radical Resection.

e14604 Background: Stage II colon cancer has a 5 year survival over 80% that is only marginally improved by the use of adjuvant treatments, so the decision of starting an adjuvant treatment, especially in older adults, has to be individualized. Methods: 205 patients were included between January 2004 and December 2008. We assessed the clinical and pathological risk factors commonly used to indicate adjuvant treatment and their impact on survival, cancer specific DFS and DFS using a multivariate COX regression. We studied the adequacy of adjuvant treatment comparing the prevalence of risk factors between patients who received adjuvant chemotherapy and patient who didn’t receive it. Results: Baseline characteristics of the patients are listed in Table. There was a positive association between a high preoperatory CEA, an insufficient nº of excised lymph nodes and the presence of lymphovascular invasion and a higher risk of relapse. The median DFS, cancer specific DFS and OS was also worse. Patients who didn’t receive adjuvant treatment had a worse performance score, and a higher age. Patients who received adjuvant treatment had higher rate of risk factor. No differences in the median number of excised lymph nodes were found between these two groups but patients with a insufficient number of lymph nodes resected also received more adjuvant treatment. The 5 year survival was 77% (follow up 76 months). 30 deaths from other causes, 7 new colorectal cancers, 11 tumors of other origin and 42 recurrences were observed. Median overall survival was105 months, disease free survival 77 months and cancer specific DFS of 94 months. Patients who received adjuvant chemotherapy had a better OS, DFS and (74, vs 64 months), and cancer specific DFS(median 98 versus 83 months). In patients over 75 the OS, DFS, and cancer specific DFS was the same in adjuvant treatment and non adjuvant treatment group. Even with a higher percentage of higher risk patients the 5year survival for patient under 75 was better for patients who received adjuvant treatment. Conclusions: Although the use of molecular biomarkers (from the determination of microsatellite instability to molecular signatures) is increasing, they must be taken into consideration alongside the traditional pathological risk factors.